SCHEMBL12772014

SCHEMBL12772014

CC(C)c1cccc(CN(c2ccccc2)c2ccccc2)c1P(Cl)Cl

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
GAA P10253 1/20 0.33
ALOX12 P18054 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NR3C2 P08235 1/20 0.32
GABRA1 P14867 3/20 0.32
GABRG2 P18507 2/20 0.32
GABRB3 P28472 2/20 0.32
SIGMAR1 Q99720 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CACNA2D1 P54289 2/20 0.31
CACNA1B Q00975 2/20 0.31
CACNB1 Q02641 2/20 0.31
GABRB2 P47870 2/20 0.31
FAAH O00519 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12772034 0.87 MEN1 (0.36) GAAALOX12NPSR1SIGMAR1MEN1
SCHEMBL12771999 0.81 SLC6A4 (0.42) GABRA1GABRG2GABRB3MEN1KMT2A
SCHEMBL12772024 0.81 CNR2 (0.36) GAAALOX12NPSR1SIGMAR1TSHR
SCHEMBL12772019 0.80 ESR1 (0.46) ESR1ESR2GAANR3C2NOS2
SCHEMBL12771991 0.79 TSHR (0.36) GABRA1GABRG2GABRB3MEN1KMT2A
SCHEMBL12772043 0.78 KDM4E (0.43) MEN1KMT2ACYP1A2TSHRPOLB
SCHEMBL12772015 0.77 ESR1 (0.34) ESR1ESR2NPSR1NR3C2CA2
SCHEMBL12774308 0.74 SIGMAR1 (0.33) GABRA1GABRG2GABRB3SIGMAR1KMT2A
SCHEMBL12774330 0.73 SIGMAR1 (0.37) GABRA1GABRG2GABRB3SIGMAR1KMT2A
SCHEMBL12772013 0.71 TAAR1 (0.36) ESR1ESR2NR3C2NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915455-B2 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-03-29 US disclosed
US-7915455-B2 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-03-29 US disclosed
US-20090143620-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED 2009-06-04 US disclosed
US-7482414-B2 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-27 US disclosed
US-7482414-B2 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-27 US disclosed
US-20070135600-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-06-14 US disclosed
US-20070135600-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135600-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex AP1M1, OR10J3, AP2M1 ESR1 372/4885ESR2 982/4885GAA 4726/4885
US-20090143620-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex AP1M1, OR10J3, AP2M1 ESR1 372/4885ESR2 982/4885GAA 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.